Location and transport

Home
| Research
| Clinical trials
| Hepatology

Hepatology

Phase III, open-label, single-group study to evaluate the safety and efficacy of TMC435 plus pegylated interferon alfa-2a and ribavirin administered for 12 weeks in untreated subjects with chronic HCV infection of genotype 1 '
Follow-up study to evaluate the resistance and durability of the response to treatment with AbbVie direct-acting anitivirals (ADA) in subjects who participated in phase 2 or phase 3 clinical trials for the treatment of chronic hepatitis C virus infection
Phase 3, randomized, open and controlled study of a non-interferon regimen with active ingredient BI 207127 in combination with Fladaprevir and Ribavirin, compared to Telaprevir in combination with pegylated interferon alpha and ribavirin for the treatment of chronic hepatitis virus infection C (HCV) genotype 1b in patients without previous treatment
Phase 2 study, open, of daclatasvir (BMS-790052) and TMC435 in combination with or without ribavirin (RBV), for the treatment of previously untreated subjects or subjects with no response to previous treatment with penginterferon alfa (peglFN) with hepatitis C chronic genotype 1
Retrospective observational study to describe the response to lead-in with peginterferon / ribavirin as a clinical decision tool in patients treated with Vietrelis (boceprevir)
A randomized, double-blind, controlled study to evaluate the efficacy and safety of the combination ABT-450 / ritonavir / ABT-267 (ABT-450 / r / ABT267) and ABT-333 with and without ribavirin (RBV) in adults with chronic infection with Hepatitis C virus genotype 1b, not previously treated (PEARL-III)
Comparative Assessement of effectiveness of antiviral therapies in Hepatitis C (CMPASS)
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT450 / ritonavir / ABT-267 and ABT-333 administered together with ribavirin (RBV) in adults with chronic infection with hepatitis C virus (HCV) ) of genotype1, previously treated (SAPPHIRE II)
Nested, retrospective, observational and non-interventional case-control study to evaluate the risk of thromboembolic events associated with surgery and eltrompag exposure in ENABLE studies
Randomized, open, multicenter study to evaluate the antiviral activity, safety and pharmacokinetics of ABT-450, with ritonavir (ABT-450 / r) in combination with ABT-267 and / or ABT-333, with or without ribavirin ( RBV), for 8, 12 or 24 weeks to patients with chronic hepatitis C virus genotype 1 infection who have not received prior treatment or no responders

14 results

Pages: 1 2 next >

Research

Clinical trials

Location and transport

Hospital Quirónsalud Valencia

Avda. Blasco Ibáñez, 14
46010 Valencia Valencia

© 2018 Quirónsalud - All rights reserved